One Nucleus Genesis Digital 2020 – Key takeaways from our cell and gene therapy panel session
8+2+1 plus what? How UK data and market exclusivity rights will be affected from 1 January 2021
作者 Alison Dennis 以及 Dr Paul England
Biologics and biosimilars litigation update
作者 Matthew Royle, Ph.D. 以及 Dr. Nora E. Wessendorf, LL.M. (Washington)
SPC for ezetimibe/simvastatin considered invalid in preliminary relief proceedings
Targeted treatments – Part 3: the power of orphan drug protection
Targeted treatments – Part 1: Targeted treatments: patents for particular populations
Adrian Toutoungi, Josef Fuss and Matt Caskie discuss how biotech has managed its finances during the pandemic
作者 Adrian Toutoungi 以及 Josef Fuss